PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+17.12%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$3.44B
AUM Growth
+$3.44B
(+1.8%)
Cap. Flow
-$426M
Cap. Flow
% of AUM
-12.37%
Top 10 Holdings %
Top 10 Hldgs %
43.73%
Holding
111
New
9
Increased
21
Reduced
33
Closed
19
Top Buys
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$114M |
| 2 |
Akero Therapeutics
AKRO
|
$66.2M |
| 3 |
Vir Biotechnology
VIR
|
$44.5M |
| 4 |
Medtronic
MDT
|
$41.1M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$35.2M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amicus Therapeutics
FOLD
$2.34B
| $347M | 10.06% | 27,662,917 | – | – |
|
|
CERE
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $321M | 9.28% | 10,088,385 +3,576,658 | +55% | +$114M |
|
|
LIAN
3
DELISTED
LianBio American Depositary Shares
LIAN
| $131M | 3.8% | 57,558,451 | – | – |
|
4
Arcellx
ACLX
$3.85B
| $127M | 3.68% | 4,016,397 +174,658 | +5% | +$5.52M |
|
5
Amylyx Pharmaceuticals
AMLX
$836M
| $105M | 3.04% | 4,873,919 -1,160,725 | -19% | -$25M |
|
6
Iovance Biotherapeutics
IOVA
$807M
| $98.8M | 2.86% | 14,036,410 -1,303,325 | -8% | -$9.18M |
|
7
Aldeyra Therapeutics
ALDX
$351M
| $95.2M | 2.76% | 11,350,085 | – | – |
|
|
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $94.1M | 2.72% | 3,624,182 +8,799 | +0.2% | +$228K |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $93M | 2.69% | 4,397,116 +1,663,326 | +61% | +$35.2M |
|
10
Nuvalent
NUVL
$5.52B
| $92.6M | 2.68% | 2,194,821 -105,227 | -5% | -$4.44M |
|
|
11
Akero Therapeutics
AKRO
$3.74B
| $90.6M | 2.62% | 1,940,675 +1,417,150 | +271% | +$66.2M |
|
12
Vaxcyte
PCVX
$4B
| $80.6M | 2.33% | 1,614,122 +444,122 | +38% | +$22.2M |
|
13
MeiraGTx Holdings
MGTX
$587M
| $76.1M | 2.2% | 11,331,103 +4,367,826 | +63% | +$29.4M |
|
14
Apellis Pharmaceuticals
APLS
$3.48B
| $74M | 2.14% | 812,037 +256,693 | +46% | +$23.4M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $70M | 2.03% | 302,987 -347,575 | -53% | -$80.3M |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $68.3M | 1.98% | 670,206 -1,499,070 | -69% | -$153M |
|
17
Treace Medical Concepts
TMCI
$464M
| $56.7M | 1.64% | 2,217,250 -225,000 | -9% | -$5.76M |
|
18
Lyra Therapeutics
LYRA
$11.5M
| $52.4M | 1.52% | 12,757,562 +3,610,832 | +39% | +$14.8M |
|
|
19
Vir Biotechnology
VIR
$686M
| $48M | 1.39% | 1,958,264 +1,816,070 | +1,277% | +$44.5M |
|
20
Immunovant
IMVT
$2.56B
| $47.9M | 1.39% | 2,523,783 +1,231,925 | +95% | +$23.4M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $47.1M | 1.36% | 1,223,377 -608,797 | -33% | -$23.4M |
|
22
ADMA Biologics
ADMA
$4.12B
| $43.9M | 1.27% | 11,900,255 | – | – |
|
23
RAPT Therapeutics
RAPT
$188M
| $42.8M | 1.24% | 2,288,493 -3,115 | -0.1% | -$58.3K |
|
24
Viridian Therapeutics
VRDN
$1.5B
| $42.3M | 1.22% | 1,776,386 +40,000 | +2% | +$952K |
|
|
25
Medtronic
MDT
$119B
| $41.1M | 1.19% | +467,000 | New | +$41.1M |
|